Track market-moving stories before they get noisy

SASOL LIMITED - BUSINESS PERFORMANCE METRICS FOR THE YEAR ENDED 30 JUNE 2026 PR Newswire JOHANNESBURG, July 21,

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC grew its position in shares of CONMED Corporation (NYSE:CNMD – Free Report) by 39.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 582,733 shares of the company’s stock after buying an additional 166,301 shares during the quarter. Allspring Global Investments Holdings LLC owned 1.94% of CONMED worth $20,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Kestra Advisory Services LLC purchased a new stake in shares of CONMED during the 4th quarter valued at about $26,000. Kelleher Financial Advisors bought a new position in shares of CONMED in the 3rd quarter worth approximately $28,000. Aster Capital Management DIFC Ltd boosted its holdings in shares of CONMED by 409.2% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 723 shares of the company’s stock worth $29,000 after buying an additional 581 shares during the last quarter. Quarry LP boosted its holdings in shares of CONMED by 244.8% in the third quarter. Quarry LP now owns 869 shares of the company’s stock worth $41,000 after buying an additional 617 shares during the last quarter. Finally, Rockefeller Capital Management L.P. grew its position in CONMED by 48.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,043 shares of the company’s stock valued at $42,000 after buying an additional 341 shares during the period.

Analyst Ratings Changes Several research firms have weighed in on CNMD. Zacks Research downgraded shares of CONMED from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Bank of America restated an “underperform” rating and issued a $40.00 price objective on shares of CONMED in a research note on Monday, June 29th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of CONMED in a report on Thursday, June 4th. Wells Fargo & Company set a $39.00 target price on CONMED in a research report on Monday, July 13th. Finally, BMO Capital Markets initiated coverage on CONMED in a report on Wednesday, July 8th. They set a “market perform” rating and a $36.00 price target for the company. Five analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, CONMED currently has an average rating of “Reduce” and a consensus target price of $38.80.

Check Out Our Latest Stock Analysis on CNMD

CONMED Price Performance CNMD stock opened at $43.51 on Tuesday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.29. The company’s fifty day moving average price is $35.98 and its 200-day moving average price is $38.36. CONMED Corporation has a one year low of $31.44 and a one year high of $56.63. The company has a market capitalization of $1.31 billion, a PE ratio of 24.58, a price-to-earnings-growth ratio of 3.19 and a beta of 0.93.

CONMED (NYSE:CNMD – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The company had revenue of $317.05 million for the quarter, compared to the consensus estimate of $310.64 million. CONMED had a net margin of 4.00% and a return on equity of 13.84%. CONMED’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.95 EPS. On average, equities analysts anticipate that CONMED Corporation will post 4.38 EPS for the current fiscal year.

CONMED Profile (Free Report)

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.

See Also Five stocks we like better than CONMED The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEThe New Germany Fund, Inc. $GF Shares Sold by Allspring Global Investments Holdings LLC

NEXT HEADLINE »Allspring Global Investments Holdings LLC Purchases 104,466 Shares of Kontoor Brands, Inc. $KTB

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC lowered its stake in Ameris Bancorp (NASDAQ:ABCB – Free Report) by 23.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 270,762 shares of the bank’s stock after selling 83,312 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.40% of Ameris Bancorp worth $21,255,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also bought and sold shares of ABCB. Royal Bank of Canada raised its holdings in Ameris Bancorp by 9.5% during the first quarter. Royal Bank of Canada now owns 29,288 shares of the bank’s stock valued at $1,687,000 after acquiring an additional 2,546 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Ameris Bancorp by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 39,181 shares of the bank’s stock valued at $2,256,000 after acquiring an additional 1,703 shares in the last quarter. NewEdge Advisors LLC lifted its stake in Ameris Bancorp by 36.7% in the 1st quarter. NewEdge Advisors LLC now owns 11,651 shares of the bank’s stock worth $671,000 after purchasing an additional 3,129 shares in the last quarter. United Services Automobile Association bought a new position in shares of Ameris Bancorp during the 1st quarter valued at about $243,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Ameris Bancorp by 7.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 187,024 shares of the bank’s stock valued at $10,767,000 after purchasing an additional 13,633 shares in the last quarter. Hedge funds and other institutional investors own 91.60% of the company’s stock.

Ameris Bancorp Trading Down 1.5% Shares of NASDAQ ABCB opened at $90.88 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.00 and a current ratio of 1.02. The business’s 50 day moving average price is $87.30 and its 200-day moving average price is $82.92. Ameris Bancorp has a fifty-two week low of $64.64 and a fifty-two week high of $93.22. The company has a market cap of $6.12 billion, a price-to-earnings ratio of 17.44 and a beta of 0.91.

Ameris Bancorp (NASDAQ:ABCB – Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The bank reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. Ameris Bancorp had a return on equity of 9.57% and a net margin of 21.46%.The company had revenue of $314.36 million during the quarter, compared to analysts’ expectations of $309.58 million. During the same quarter in the previous year, the business earned $1.28 EPS. On average, sell-side analysts expect that Ameris Bancorp will post 4.99 earnings per share for the current year.

Ameris Bancorp Announces Dividend The business also recently announced a quarterly dividend, which was paid on Monday, July 6th. Stockholders of record on Tuesday, June 30th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, June 30th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. Ameris Bancorp’s dividend payout ratio (DPR) is 12.58%.

Analysts Set New Price Targets Several brokerages have recently issued reports on ABCB. Stephens lifted their target price on Ameris Bancorp from $87.00 to $90.00 and gave the stock an “equal weight” rating in a report on Monday, April 27th. Morgan Stanley upgraded Ameris Bancorp to an “overweight” rating in a research report on Wednesday, June 24th. DA Davidson upped their target price on shares of Ameris Bancorp from $94.00 to $98.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Piper Sandler downgraded shares of Ameris Bancorp from an “overweight” rating to a “neutral” rating and set a $96.00 price target for the company. in a report on Sunday, July 12th. Finally, Raymond James Financial lowered Ameris Bancorp from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 1st. Three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $92.67.

View Our Latest Research Report on ABCB

Ameris Bancorp Profile (Free Report)

Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. Through its principal subsidiary, Ameris Bank, the company offers a broad range of commercial and retail banking services to individuals, small businesses, middle market companies and agricultural customers. Its core business lines encompass deposit services, lending solutions, treasury management, mortgage origination and servicing, insurance products and wealth management.

Ameris Bancorp operates a network of branches and loan production offices across the southeastern United States, including Georgia, Alabama, Florida, North Carolina, South Carolina and Tennessee.

Featured Stories Five stocks we like better than Ameris Bancorp The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Ameris Bancorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ameris Bancorp and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEVericel Corporation $VCEL Shares Sold by Allspring Global Investments Holdings LLC

NEXT HEADLINE »Allspring Global Investments Holdings LLC Sells 38,930 Shares of People Incorporated Common Stock $PPLI

BFA Law has filed a securities fraud class action lawsuit on behalf of Hub Group investors after its stock plummeted 18% after it announced its financial statements were materially misstated and should no longer be relied upon.

, /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Hub Group Inc. (NASDAQ: HUBG) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Hub Group, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/hub-group-class-action-lawsuit.

Key Details of the HUBG ($HUBG) Class Action:

Lead Plaintiff Deadline: August 28, 2026 Alleged Misconduct: Securities fraud relating to Hub Group's financial results, revenue recognition, accounting of costs, internal controls, and prospects for/drivers of growth Largest Stock Drop: February 6, 2026 – 18% Stock Drop Court: U.S. District Court for the Northern District of Illinois Filing Law Firm: Bleichmar Fonti & Auld ("BFA Law") Action: Contact BFA Law to discuss your rights Investors have until August 28, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Hub Group securities. The class action is pending in the U.S. District Court for the Northern District of Illinois. It is captioned Lawler v. Hub Group, Inc., No. 1:26-cv-07596.

Why is Hub Group Being Sued for Securities Fraud?

Hub Group is a transportation and logistics freight carrier that provides trucking and related services to operators across the supply chain. Hub Group services a customer base extending across various industries, including retail, consumer products, automotive, and durable goods, and reports to be one of the largest freight transportation providers in North America. 

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements concerning the premature and incorrect revenue recognition of certain transactions, the understatement of purchased transportation costs and accounts payable, the effectiveness of internal controls, and the Hub Group's drivers of financial results and growth.

Why did Hub Group's Stock Drop?

On February 5, 2026, Hub Group announced that the Company's financial statements for the first three quarters of 2025 should not be relied upon and would be restated due to "an error that resulted in the understatement of purchased transportation costs and accounts payable in the first nine months of 2025." Hub Group revealed that its reports for those quarters "were in each case materially misstated due to the aforementioned error and should no longer be relied upon" and that "the Company [wa]s also continuing to assess the effectiveness of its disclosure controls and procedures and internal control over financial reporting and appropriate remediation steps."  Hub Group also estimated that "[t]he total amount of the reduction to accounts payable and purchased transportation costs related to this issue that was recorded during these periods is $77 million."

This news caused the price of Hub Group stock to decline roughly 18%, from $51.33 per share at close on February 5, 2026, to $41.96 per share at close on February 6, 2026.

On May 12, 2026, Hub Group announced that it had "identified certain transactions that were prematurely or incorrectly recognized or not adequately supported," causing its 2023 and 2024 annual reports filed with the SEC to be "materially misstated," such that they "should no longer be relied upon."  Hub Group did not quantify the expected misstatement, although it "expect[ed] to conclude that it did not maintain effective disclosure controls and procedures and internal control over financial reporting for each of the years ended December 31, 2024 and 2023."

This news caused the price of Hub Group stock to decline a further 13%, from $41.86 per share at close on May 11, 2026, to $36.62 per share at close on May 12, 2026.

Click here for more information: https://www.bfalaw.com/cases/hub-group-class-action-lawsuit.

What Can You Do?

If you invested in Hub Group, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/hub-group-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space."  One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."  

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/hub-group-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

SOURCE Bleichmar Fonti & Auld LLP

Posted by Defense World Staff on Jul 21st, 2026

Andar Capital Management HK Ltd grew its position in Vicor Corporation (NASDAQ:VICR – Free Report) by 71.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,000 shares of the electronics maker’s stock after acquiring an additional 23,000 shares during the quarter. Vicor comprises approximately 7.6% of Andar Capital Management HK Ltd’s portfolio, making the stock its 6th biggest position. Andar Capital Management HK Ltd owned approximately 0.12% of Vicor worth $8,855,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Vicor by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 2,534,534 shares of the electronics maker’s stock worth $277,785,000 after purchasing an additional 60,963 shares during the period. Dimensional Fund Advisors LP grew its position in Vicor by 4.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 578,515 shares of the electronics maker’s stock valued at $28,759,000 after buying an additional 25,393 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Vicor by 1,542.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 439,820 shares of the electronics maker’s stock valued at $48,205,000 after buying an additional 413,038 shares during the period. The Manufacturers Life Insurance Company raised its position in Vicor by 3,918.9% during the 4th quarter. The Manufacturers Life Insurance Company now owns 432,189 shares of the electronics maker’s stock worth $47,368,000 after buying an additional 421,435 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in Vicor by 39.6% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 374,088 shares of the electronics maker’s stock worth $41,000,000 after buying an additional 106,206 shares during the last quarter. 47.45% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades Several research analysts recently issued reports on the stock. Needham & Company LLC increased their price target on shares of Vicor to $400.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Wall Street Zen cut Vicor from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Weiss Ratings reissued a “hold (c+)” rating on shares of Vicor in a research note on Monday, June 1st. Roth Capital raised their price target on Vicor from $285.00 to $375.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Finally, Craig Hallum lifted their price target on Vicor to $450.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Three investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $408.33.

Read Our Latest Stock Report on Vicor

Insider Buying and Selling at Vicor In other Vicor news, CEO Patrizio Vinciarelli sold 20,000 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $342.10, for a total transaction of $6,842,000.00. Following the sale, the chief executive officer owned 8,828,090 shares in the company, valued at approximately $3,020,089,589. This represents a 0.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 392,682 shares of company stock worth $123,899,833. Company insiders own 28.30% of the company’s stock.

Vicor Trading Down 2.8% VICR stock opened at $230.99 on Tuesday. The company’s 50-day moving average price is $297.90 and its 200 day moving average price is $221.96. Vicor Corporation has a 52 week low of $41.76 and a 52 week high of $382.65. The company has a market cap of $10.53 billion, a P/E ratio of 77.25 and a beta of 2.33.

Vicor (NASDAQ:VICR – Get Free Report) last posted its earnings results on Tuesday, April 21st. The electronics maker reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.40 by $0.04. The company had revenue of $112.97 million for the quarter, compared to analyst estimates of $109.05 million. Vicor had a return on equity of 20.21% and a net margin of 28.98%.Vicor’s revenue was up 20.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.06 earnings per share. On average, equities research analysts expect that Vicor Corporation will post 2.94 earnings per share for the current year.

About Vicor (Free Report)

Vicor Corporation is a designer and manufacturer of modular power components and systems, serving a wide range of industries that demand high performance and efficiency. Headquartered in Andover, Massachusetts, the company develops power conversion solutions that help customers optimize energy delivery in applications from telecommunications and data centers to industrial and automotive systems.

The company’s product portfolio includes high-density DC-DC converters, AC-DC front-end modules, point-of-load regulators and complete power systems that combine multiple conversion stages in a single package.

Further Reading Five stocks we like better than Vicor The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding VICR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vicor Corporation (NASDAQ:VICR – Free Report).

Receive News & Ratings for Vicor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicor and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAmova Asset Management Americas Inc. Grows Stake in BP p.l.c. $BP

NEXT HEADLINE »Andra AP fonden Has $61.73 Million Holdings in AbbVie Inc. $ABBV

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC lowered its holdings in shares of The Ensign Group, Inc. (NASDAQ:ENSG – Free Report) by 10.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 115,803 shares of the company’s stock after selling 13,953 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.20% of The Ensign Group worth $23,172,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of The Ensign Group by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 161,946 shares of the company’s stock worth $20,956,000 after purchasing an additional 14,590 shares during the last quarter. Geneos Wealth Management Inc. grew its stake in The Ensign Group by 150.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 383 shares of the company’s stock worth $50,000 after acquiring an additional 230 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of The Ensign Group by 65.9% during the second quarter. EverSource Wealth Advisors LLC now owns 536 shares of the company’s stock worth $83,000 after acquiring an additional 213 shares during the period. Amundi increased its position in shares of The Ensign Group by 480,216.7% during the second quarter. Amundi now owns 57,638 shares of the company’s stock worth $8,583,000 after acquiring an additional 57,626 shares during the period. Finally, Brown Advisory Inc. increased its position in shares of The Ensign Group by 26.1% during the second quarter. Brown Advisory Inc. now owns 2,037 shares of the company’s stock worth $314,000 after acquiring an additional 421 shares during the period. Institutional investors own 96.12% of the company’s stock.

Insider Buying and Selling at The Ensign Group In related news, Director Barry M. Smith sold 700 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $164.28, for a total transaction of $114,996.00. Following the sale, the director owned 21,352 shares of the company’s stock, valued at $3,507,706.56. This trade represents a 3.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades A number of analysts recently issued reports on the company. Truist Financial lowered their price target on The Ensign Group from $215.00 to $202.00 and set a “hold” rating for the company in a report on Tuesday, July 14th. Wall Street Zen upgraded The Ensign Group from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Weiss Ratings lowered The Ensign Group from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 16th. Royal Bank Of Canada reiterated an “outperform” rating on shares of The Ensign Group in a report on Tuesday, June 9th. Finally, Zacks Research downgraded The Ensign Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $213.50.

Check Out Our Latest Research Report on ENSG

The Ensign Group Price Performance NASDAQ ENSG opened at $172.04 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.56 and a current ratio of 1.56. The firm’s 50 day moving average price is $165.91 and its 200-day moving average price is $184.03. The Ensign Group, Inc. has a 52-week low of $134.79 and a 52-week high of $218.00. The company has a market cap of $10.05 billion, a PE ratio of 28.02, a P/E/G ratio of 1.68 and a beta of 0.69.

The Ensign Group (NASDAQ:ENSG – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported $1.85 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.06. The company had revenue of $1.39 billion during the quarter, compared to the consensus estimate of $1.40 billion. The Ensign Group had a net margin of 6.89% and a return on equity of 16.78%. The Ensign Group’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.52 earnings per share. The Ensign Group has set its FY 2026 guidance at 7.480-7.620 EPS. Sell-side analysts forecast that The Ensign Group, Inc. will post 6.82 EPS for the current fiscal year.

The Ensign Group Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.065 dividend. This represents a $0.26 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Tuesday, June 30th. The Ensign Group’s payout ratio is presently 4.23%.

The Ensign Group Profile (Free Report)

The Ensign Group, Inc is a diversified provider of post-acute healthcare services in the United States, operating a network of skilled nursing, assisted living, independent living, home health and hospice care centers. The company’s model emphasizes integrated care by employing multidisciplinary teams—including nursing staff, therapists and physicians—to deliver personalized rehabilitation and long-term care services for seniors and other patients recovering from injury, illness or surgery.

Through its owned and managed centers, The Ensign Group offers a broad spectrum of rehabilitation services such as physical, occupational and speech therapy.

Featured Articles Five stocks we like better than The Ensign Group The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ENSG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Ensign Group, Inc. (NASDAQ:ENSG – Free Report).

Receive News & Ratings for The Ensign Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Ensign Group and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Sells 14,398 Shares of Entergy Corporation $ETR

NEXT HEADLINE »Allspring Global Investments Holdings LLC Buys 148,067 Shares of Levi Strauss & Co. $LEVI

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 78.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,697 shares of the biopharmaceutical company’s stock after acquiring an additional 38,157 shares during the period. Andra AP fonden owned approximately 0.06% of Alnylam Pharmaceuticals worth $28,685,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. MV Capital Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $27,000. Golden State Wealth Management LLC increased its stake in Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares in the last quarter. Finally, Manchester Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 72 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades Several equities analysts have recently issued reports on the company. Truist Financial decreased their price objective on Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a report on Monday, July 13th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a report on Friday, May 1st. Citigroup assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target for the company. Finally, Bank of America cut their price target on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $455.31.

Check Out Our Latest Research Report on ALNY

Insider Activity at Alnylam Pharmaceuticals In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Performance Shares of NASDAQ ALNY opened at $272.67 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $266.27 and a 12-month high of $495.55. The company has a market cap of $36.40 billion, a PE ratio of 74.50 and a beta of 0.27. The stock has a 50 day simple moving average of $293.92 and a 200-day simple moving average of $319.69. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the company earned ($0.44) earnings per share. The company’s revenue for the quarter was up 96.4% on a year-over-year basis. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.26 EPS for the current year.

About Alnylam Pharmaceuticals (Free Report)

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

See Also Five stocks we like better than Alnylam Pharmaceuticals The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Grows Stake in McDonald’s Corporation $MCD

NEXT HEADLINE »Andra AP fonden Has $25.74 Million Holdings in AppLovin Corporation $APP

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC decreased its holdings in shares of Axcelis Technologies, Inc. (NASDAQ:ACLS – Free Report) by 2.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 258,536 shares of the semiconductor company’s stock after selling 7,479 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.84% of Axcelis Technologies worth $24,693,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of ACLS. UBS Group AG boosted its stake in shares of Axcelis Technologies by 67.6% during the fourth quarter. UBS Group AG now owns 213,388 shares of the semiconductor company’s stock valued at $17,144,000 after acquiring an additional 86,065 shares during the last quarter. Burney Co. acquired a new position in Axcelis Technologies in the 4th quarter valued at about $1,986,000. Peterson Wealth Services lifted its holdings in Axcelis Technologies by 1,750.8% in the 4th quarter. Peterson Wealth Services now owns 7,403 shares of the semiconductor company’s stock valued at $595,000 after purchasing an additional 7,003 shares in the last quarter. ABN Amro Investment Solutions lifted its holdings in Axcelis Technologies by 42.6% in the 4th quarter. ABN Amro Investment Solutions now owns 24,798 shares of the semiconductor company’s stock valued at $1,992,000 after purchasing an additional 7,408 shares in the last quarter. Finally, Intech Investment Management LLC boosted its stake in shares of Axcelis Technologies by 129.0% during the 4th quarter. Intech Investment Management LLC now owns 40,463 shares of the semiconductor company’s stock worth $3,251,000 after purchasing an additional 22,792 shares during the last quarter. 89.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets Several equities analysts recently issued reports on ACLS shares. Bank of America upped their price objective on shares of Axcelis Technologies from $130.00 to $156.00 and gave the company an “underperform” rating in a research note on Tuesday, June 23rd. B. Riley Financial raised shares of Axcelis Technologies from a “neutral” rating to a “buy” rating and set a $150.00 target price for the company in a research note on Monday, April 20th. Weiss Ratings lowered Axcelis Technologies from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, May 12th. Finally, Zacks Research upgraded Axcelis Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, April 20th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $130.25.

View Our Latest Stock Report on Axcelis Technologies

Insider Activity at Axcelis Technologies In other news, VP Todd Sutton sold 2,000 shares of Axcelis Technologies stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $159.99, for a total value of $319,980.00. Following the transaction, the vice president directly owned 6,360 shares of the company’s stock, valued at $1,017,536.40. The trade was a 23.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Eileen Evans sold 926 shares of Axcelis Technologies stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $155.51, for a total transaction of $144,002.26. Following the transaction, the executive vice president directly owned 31,295 shares in the company, valued at approximately $4,866,685.45. This trade represents a 2.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 34,795 shares of company stock valued at $5,344,383 over the last three months. Insiders own 0.49% of the company’s stock.

Axcelis Technologies Price Performance Axcelis Technologies stock opened at $131.70 on Tuesday. Axcelis Technologies, Inc. has a 1 year low of $65.64 and a 1 year high of $193.78. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 4.59. The firm has a 50 day moving average price of $158.72 and a 200 day moving average price of $120.41. The company has a market cap of $4.05 billion, a price-to-earnings ratio of 41.03, a PEG ratio of 9.66 and a beta of 1.88.

Axcelis Technologies (NASDAQ:ACLS – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The semiconductor company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.01. The company had revenue of $198.96 million for the quarter, compared to the consensus estimate of $195.03 million. Axcelis Technologies had a net margin of 11.93% and a return on equity of 12.19%. Axcelis Technologies’s revenue was up 3.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.88 earnings per share. Axcelis Technologies has set its Q2 2026 guidance at 0.900- EPS. Sell-side analysts predict that Axcelis Technologies, Inc. will post 3.21 earnings per share for the current year.

Axcelis Technologies Profile (Free Report)

Axcelis Technologies, Inc is a leading developer and manufacturer of ion implantation and cleaning equipment used in the fabrication of semiconductor chips. The company specializes in high-current, medium-current and high-energy ion implantation systems, which are critical for introducing precisely controlled dopants into silicon wafers. Axcelis also offers plasma-based cleaning and dry strip tools that support advanced process nodes in logic, memory and power device manufacturing.

The company’s product portfolio encompasses single-wafer and multi-wafer cluster tools designed to deliver high throughput, accuracy and uniformity for semiconductor process steps.

Featured Stories Five stocks we like better than Axcelis Technologies The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Axcelis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcelis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Raises Stake in Pattern Group Inc. $PTRN

NEXT HEADLINE »Allspring Global Investments Holdings LLC Raises Stock Holdings in Ingram Micro Holding Corporation $INGM

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 44.9% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 954,855 shares of the biopharmaceutical company’s stock after buying an additional 296,042 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.56% of ACADIA Pharmaceuticals worth $21,312,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ACAD. Illinois Municipal Retirement Fund grew its stake in ACADIA Pharmaceuticals by 12.7% during the first quarter. Illinois Municipal Retirement Fund now owns 71,183 shares of the biopharmaceutical company’s stock valued at $1,585,000 after acquiring an additional 7,996 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in shares of ACADIA Pharmaceuticals by 30.6% during the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 12,923 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 3,026 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of ACADIA Pharmaceuticals by 3.1% during the first quarter. Principal Financial Group Inc. now owns 768,224 shares of the biopharmaceutical company’s stock valued at $17,101,000 after purchasing an additional 22,868 shares in the last quarter. Fifth Third Bancorp grew its position in shares of ACADIA Pharmaceuticals by 5,053.5% during the first quarter. Fifth Third Bancorp now owns 31,694 shares of the biopharmaceutical company’s stock valued at $706,000 after purchasing an additional 31,079 shares in the last quarter. Finally, Hsbc Holdings PLC increased its holdings in shares of ACADIA Pharmaceuticals by 67.4% in the first quarter. Hsbc Holdings PLC now owns 44,008 shares of the biopharmaceutical company’s stock worth $977,000 after purchasing an additional 17,722 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

Wall Street Analysts Forecast Growth A number of equities research analysts recently commented on the company. Bank of America boosted their target price on ACADIA Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $37.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, June 29th. Citigroup boosted their price objective on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Canaccord Genuity Group raised their price objective on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Weiss Ratings cut ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 1st. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.94.

View Our Latest Research Report on ACAD

ACADIA Pharmaceuticals Stock Performance Shares of NASDAQ ACAD opened at $25.09 on Tuesday. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $19.69 and a fifty-two week high of $28.35. The company has a market cap of $4.30 billion, a price-to-earnings ratio of 11.40, a PEG ratio of 18.44 and a beta of 0.80. The business’s 50 day moving average price is $22.98 and its 200-day moving average price is $23.28.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The company had revenue of $268.10 million during the quarter, compared to the consensus estimate of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.11 earnings per share. Sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.37 earnings per share for the current year.

Insider Activity at ACADIA Pharmaceuticals In other news, insider James Kihara sold 5,401 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the transaction, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. This represents a 18.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Mark C. Schneyer sold 3,506 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $76,395.74. Following the transaction, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. This represents a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,239 shares of company stock valued at $219,813 in the last ninety days. Insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Profile (Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.

Featured Stories Five stocks we like better than ACADIA Pharmaceuticals The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Has $21.26 Million Position in ITT Inc. $ITT

NEXT HEADLINE »Allspring Global Investments Holdings LLC Reduces Stock Position in Sempra Energy $SRE

A securities fraud class action lawsuit has been filed on behalf of Peabody investors after its stock plummeted over 9% because Peabody allegedly misled investors regarding the coal production at Centurion, its flagship premium hard coking coal mine.

, /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Peabody Energy Corporation (NYSE:BTU) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Peabody, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/peabody-class-action-lawsuit.

Key Details of the Peabody ($BTU) Class Action:

Lead Plaintiff Deadline: August 24, 2026 Alleged Misconduct: Securities fraud relating to Peabody's statements about the coal production at Centurion, its flagship premium hard coking coal mine. Largest Alleged Stock Drop: March 30, 2026 – 9.7% stock drop Court: U.S. District Court for the Eastern District of Missouri Action: Contact BFA Law to discuss your rights Investors have until August 24, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Peabody common stock. The class action is pending in the U.S. District Court for the Eastern District of Missouri. It is captioned McGeachy v. Peabody, et al., No. 26-cv-01020.

Why is Peabody Being Sued for Securities Fraud?

Peabody is a producer of metallurgic and thermal coal that owns interests in 16 active coal mining operations in the United States and Australia.

According to the complaint, during the relevant period, Peabody announced it would be increasing production from its flagship premium hard coking coal mine, Centurion due to an acceleration of longwall operations. Peabody stated that shipments of Centurion's premium hard coking coal would expand sevenfold in 2026 to 3.5 million tons and even more beyond that time. On February 5, 2026, Peabody indicated that the team was "putting the finishing touches on the Centurion mine in advance of starting longwall mining, well ahead of its original schedule."

As alleged, in truth, the Centurion mine was facing significant commissioning challenges resulting in increased costs and volume decreases in its production.

Why did Peabody's Stock Drop?

On March 30, 2026, Peabody announced lower sales volume from the Centurion mine due to a delivery of only 250,000 tons in the first quarter. Peabody attributed the low volume to "greater than anticipated mine commissioning challenges."

This news caused the price of Peabody common stock to drop $3.82 per share, or 9.7%, from $39.50 per share on March 27, 2026, to $35.68 per share on March 30, 2026.

Then, on May 5, 2026, Peabody announced additional delays to the commissioning of the Centurion mine as well as increased costs and lower volume. Peabody stated it only expected to sell about 300,000 tons in the second quarter and reduced its full year sales outlook for Centurion from 3.5 million tons to 2.5 million tons.

This news caused the price of Peabody common stock to drop $1.52 per share, or 5.7%, from $26.52 per share on May 4, 2026, to $25.00 per share on May 5, 2025.

Click here for more information: https://www.bfalaw.com/cases/peabody-class-action-lawsuit.

What Can You Do?

If you invested in Peabody, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/peabody-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space."  One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/peabody-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

SOURCE Bleichmar Fonti & Auld LLP

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC boosted its position in CareTrust REIT, Inc. (NYSE:CTRE – Free Report) by 38.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 649,559 shares of the company’s stock after acquiring an additional 179,499 shares during the period. Allspring Global Investments Holdings LLC owned 0.29% of CareTrust REIT worth $24,118,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CTRE. Vanguard Group Inc. grew its holdings in CareTrust REIT by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 33,184,181 shares of the company’s stock worth $1,199,940,000 after acquiring an additional 210,965 shares during the period. State Street Corp lifted its stake in shares of CareTrust REIT by 1.8% in the 4th quarter. State Street Corp now owns 12,426,213 shares of the company’s stock valued at $453,411,000 after purchasing an additional 219,641 shares during the period. Wellington Management Group LLP boosted its position in shares of CareTrust REIT by 18.1% in the 4th quarter. Wellington Management Group LLP now owns 12,355,966 shares of the company’s stock worth $446,792,000 after purchasing an additional 1,893,143 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of CareTrust REIT by 108.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,493,898 shares of the company’s stock worth $234,820,000 after purchasing an additional 3,379,732 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in CareTrust REIT by 7.2% in the fourth quarter. Geode Capital Management LLC now owns 6,092,398 shares of the company’s stock valued at $220,332,000 after acquiring an additional 409,411 shares during the period. 87.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In A number of equities research analysts have recently commented on CTRE shares. KeyCorp reaffirmed an “overweight” rating and set a $46.00 price target on shares of CareTrust REIT in a research report on Friday, May 29th. Citigroup reissued a “market outperform” rating on shares of CareTrust REIT in a research note on Wednesday, June 10th. BMO Capital Markets raised their target price on shares of CareTrust REIT from $46.00 to $47.00 and gave the stock an “outperform” rating in a report on Monday, June 15th. Zacks Research raised shares of CareTrust REIT from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. Finally, Mizuho set a $45.00 price target on shares of CareTrust REIT in a report on Friday, May 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, CareTrust REIT presently has an average rating of “Buy” and a consensus target price of $44.82.

Read Our Latest Report on CareTrust REIT

CareTrust REIT Stock Performance CTRE opened at $42.39 on Tuesday. The business’s 50-day simple moving average is $39.95 and its 200 day simple moving average is $39.04. CareTrust REIT, Inc. has a 52-week low of $30.26 and a 52-week high of $43.10. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.37 and a current ratio of 2.38. The firm has a market capitalization of $10.01 billion, a PE ratio of 27.17, a PEG ratio of 1.93 and a beta of 0.76.

CareTrust REIT Dividend Announcement The company also recently declared a quarterly dividend, which was paid on Wednesday, July 15th. Shareholders of record on Tuesday, June 30th were paid a $0.39 dividend. The ex-dividend date was Tuesday, June 30th. This represents a $1.56 dividend on an annualized basis and a yield of 3.7%. CareTrust REIT’s dividend payout ratio (DPR) is currently 100.00%.

CareTrust REIT Profile (Free Report)

CareTrust REIT, Inc is a real estate investment trust based in Deerfield Beach, Florida, specializing in the ownership, acquisition and management of net-leased healthcare properties. The company primarily focuses on seniors housing and post-acute care facilities, entering into long-term, triple-net lease agreements with leading operators in the skilled nursing, assisted living, memory care, inpatient rehabilitation and specialty hospital sectors. Through its portfolio, CareTrust REIT aims to provide investors with stable and predictable rental income while supporting the ongoing demand for quality healthcare real estate across the United States.

Since its initial public offering in September 2013, CareTrust REIT has pursued a disciplined acquisition strategy, targeting properties in primary and select secondary markets.

Further Reading Five stocks we like better than CareTrust REIT The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding CTRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareTrust REIT, Inc. (NYSE:CTRE – Free Report).

Receive News & Ratings for CareTrust REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareTrust REIT and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEGarrett Motion Inc. $GTX Shares Purchased by Allspring Global Investments Holdings LLC

NEXT HEADLINE »Allspring Global Investments Holdings LLC Sells 14,398 Shares of Entergy Corporation $ETR

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC decreased its holdings in Rollins, Inc. (NYSE:ROL – Free Report) by 17.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 438,205 shares of the business services provider’s stock after selling 91,994 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.09% of Rollins worth $23,440,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Norges Bank bought a new position in shares of Rollins during the fourth quarter worth approximately $244,669,000. Pictet Asset Management Holding SA grew its position in Rollins by 188.2% during the first quarter. Pictet Asset Management Holding SA now owns 2,908,818 shares of the business services provider’s stock worth $155,335,000 after buying an additional 1,899,515 shares in the last quarter. Vanguard Group Inc. grew its position in Rollins by 4.3% during the fourth quarter. Vanguard Group Inc. now owns 38,282,523 shares of the business services provider’s stock worth $2,297,717,000 after buying an additional 1,562,241 shares in the last quarter. USS Investment Management Ltd increased its stake in Rollins by 55.9% during the 1st quarter. USS Investment Management Ltd now owns 3,131,337 shares of the business services provider’s stock worth $167,260,000 after acquiring an additional 1,123,237 shares during the period. Finally, Bessemer Group Inc. increased its stake in Rollins by 11,772.1% during the 4th quarter. Bessemer Group Inc. now owns 1,084,398 shares of the business services provider’s stock worth $65,086,000 after acquiring an additional 1,075,264 shares during the period. Institutional investors own 51.79% of the company’s stock.

Wall Street Analysts Forecast Growth A number of brokerages recently commented on ROL. Citigroup assumed coverage on Rollins in a research report on Wednesday, July 15th. They issued a “neutral” rating and a $46.00 price target on the stock. Sanford C. Bernstein cut shares of Rollins from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $70.00 to $52.00 in a research report on Friday, May 29th. Loop Capital started coverage on shares of Rollins in a research note on Monday, April 13th. They set a “hold” rating and a $56.00 price objective on the stock. The Goldman Sachs Group reissued a “buy” rating and issued a $67.00 target price on shares of Rollins in a report on Thursday, April 23rd. Finally, UBS Group set a $50.00 target price on shares of Rollins in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $60.87.

Get Our Latest Stock Report on Rollins

Rollins Stock Down 0.6% Shares of NYSE ROL opened at $44.82 on Tuesday. The company has a market cap of $21.58 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 2.77 and a beta of 0.75. The company has a current ratio of 0.65, a quick ratio of 0.59 and a debt-to-equity ratio of 0.35. Rollins, Inc. has a 12 month low of $41.50 and a 12 month high of $66.14. The stock has a 50-day moving average price of $47.05 and a two-hundred day moving average price of $54.23.

Rollins (NYSE:ROL – Get Free Report) last posted its quarterly earnings results on Wednesday, April 22nd. The business services provider reported $0.24 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.24. The company had revenue of $906.42 million for the quarter, compared to the consensus estimate of $895.17 million. Rollins had a net margin of 13.77% and a return on equity of 38.37%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the company posted $0.22 EPS. As a group, analysts forecast that Rollins, Inc. will post 1.24 earnings per share for the current fiscal year.

Key Headlines Impacting Rollins Here are the key news stories impacting Rollins this week:

Positive Sentiment: Analysts expect Rollins’ second-quarter revenue and earnings to increase, supported by acquisitions, market expansion, cross-selling and pricing power. Rollins is Set to Report Q2 Earnings: Here’s What You Should Know Positive Sentiment: Another preview said investors should watch key operating metrics, signaling that results could show continued underlying business momentum. Rollins (ROL) Q2 Earnings on the Horizon: Analysts’ Insights on Key Performance Measures Neutral Sentiment: A market commentary piece said Rollins’ revenue beat and rising EPS estimates are favorable for shareholders, but it was more interpretive than a new catalyst. What Rollins (ROL)’s Revenue Beat and Rising EPS Estimates Mean For Shareholders About Rollins (Free Report)

Rollins, Inc (NYSE: ROL) is a provider of pest and termite control services operating through a network of subsidiaries and franchises. Headquartered in Atlanta, Georgia, the company offers a broad range of pest management solutions for both residential and commercial customers, positioning itself as a specialist in protecting property and public health from pests and vectors.

Its service offerings include general pest control, termite inspection and treatment, bed bug remediation, mosquito and vector control, wildlife exclusion, and related specialty services.

Featured Articles Five stocks we like better than Rollins The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Rollins Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rollins and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Sells 125,721 Shares of Qualcomm Incorporated $QCOM

NEXT HEADLINE »Garrett Motion Inc. $GTX Shares Purchased by Allspring Global Investments Holdings LLC

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 7.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 43,198 shares of the company’s stock after selling 3,332 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.05% of IDEXX Laboratories worth $24,392,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Elyxium Wealth LLC purchased a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $3,666,459,000. J. Stern & Co. LLP grew its stake in IDEXX Laboratories by 23,694.7% in the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after buying an additional 2,642,200 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of IDEXX Laboratories by 63,503.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after buying an additional 1,442,174 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of IDEXX Laboratories by 318.1% in the 4th quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after buying an additional 592,834 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $332,265,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Down 0.6% Shares of NASDAQ:IDXX opened at $563.81 on Tuesday. The stock has a market capitalization of $44.47 billion, a P/E ratio of 41.52, a price-to-earnings-growth ratio of 3.10 and a beta of 1.55. The stock’s 50-day moving average price is $555.13 and its 200-day moving average price is $598.49. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12-month low of $513.02 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the prior year, the business posted $2.91 EPS. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analyst Upgrades and Downgrades IDXX has been the subject of a number of research analyst reports. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Finally, Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

Get Our Latest Report on IDXX

About IDEXX Laboratories (Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

See Also Five stocks we like better than IDEXX Laboratories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Has $23.57 Million Stock Holdings in Vanguard FTSE Europe ETF $VGK

NEXT HEADLINE »La-Z-Boy Incorporated $LZB Shares Acquired by Allspring Global Investments Holdings LLC

Key Takeaways:

Parsons delivers integrated industrial base modernization and advanced manufacturing solutions that accelerate mission readiness across defense and infrastructure markets worldwide.Parsons’ enterprise-wide delivery model unites expertise across its Federal Solutions and Critical Infrastructure segments to deliver complete industrial ecosystems at speed and scale.With global execution and proven programs, Parsons supports urgent national security and economic priorities driven by rising demand and sustained government investment in industrial capacity. CHANTILLY, Va., July 21, 2026 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) today highlighted its delivery of integrated industrial base modernization and advanced manufacturing solutions that are strengthening national security, enabling global infrastructure resilience, and accelerating delivery of mission-critical capabilities across defense and commercial markets.

As demand intensifies to modernize aging infrastructure and scale production of critical capabilities, Parsons delivers integrated, end-to-end solutions that transform how industrial capacity is built, modernized, and sustained. By combining deep engineering expertise, advanced technologies, and global program delivery, the company enables customers to expand production, strengthen supply chains, and deliver operational capability in real time.

“Industrial base modernization is no longer a future priority; it’s an immediate operational requirement,” said Martin Boson, president of Engineered Systems for Parsons. “We are helping redefine how the defense industrial base is modernized, integrating advanced manufacturing, infrastructure, and digital capabilities to rapidly scale production, improve readiness, and deliver mission-critical capacity for today’s and tomorrow’s threats.”

Parsons differentiates through a fully integrated delivery model that unifies planning, engineering, program and construction management, advanced manufacturing, cybersecurity, and environmental solutions expertise into a single approach. This enables the company to deliver complete industrial ecosystems rather than standalone facilities, accelerating timelines, reducing risk, and ensuring mission success. By leveraging capabilities across both its Federal Solutions and Critical Infrastructure segments, Parsons bridges traditionally siloed markets and delivers mission-aligned solutions at scale.

“Industrial base modernization requires more than expanding production; it demands the infrastructure, energy, and systems that sustain it,” said Mark Fialkowski, president of Infrastructure North America for Parsons. “We are delivering integrated solutions across critical infrastructure, from data centers and energy systems to industrial development, to help our customers strengthen resilience, enable economic growth, and build the industrial ecosystems needed to support both national security and commercial demands.”

Parsons’ capabilities span the full spectrum of defense industrial base modernization priorities, from modernizing Army munitions and ammunition facilities to upgrading legacy infrastructure across depots, arsenals, and manufacturing plants. This is demonstrated by the company’s growing role in the U.S. Army’s Organic Industrial Base, including a $169.5 million design-build contract with the U.S. Army Corps of Engineers to deliver a new Ammonium Nitrate Solution Tank Farm at Holston Army Ammunition Plant. The company also supports expanded production capacity through work on Nammo’s new rocket motor production facility in Perry, Florida, strengthening production scale, supply chain resilience, and operational readiness.

The company also delivers complex energetics and specialized facilities, as demonstrated by the Blue Grass Chemical Weapons Stockpile Destruction Project, where Parsons played a central role in the design, construction, operation, and closure of the facility that safely eliminated the nation’s remaining chemical weapons stockpile in support of critical national security objectives. This legacy chemical demilitarization expertise reflects Parsons’ ability to execute highly complex, high-consequence industrial programs requiring advanced safety, regulatory, environmental, and operational expertise.

Beyond the United States, Parsons is executing large-scale industrial and infrastructure programs globally. In the Middle East, the company is advancing economic diversification and industrial growth through initiatives such as the Al Karaana Special Economic Zone in Qatar. Our long record of developing large industrial cities and special economic zones in Saudi Arabia, dating back to the 1970s, such as Jazan and Yanbu Industrial Cities, enables integrated development and long-term resilience. Parsons also delivers mission-critical data center infrastructure across the region to support AI, digital transformation, and secure operations, while strengthening supply chains tied to critical minerals and advanced manufacturing.

In parallel, Parsons is advancing high-tech manufacturing ecosystems, including semiconductor-related infrastructure that strengthens domestic and allied production capacity and enables more resilient supply chains through critical minerals sourcing, processing, and distribution.

The company further integrates digital engineering, environmental remediation, and critical infrastructure protection to modernize legacy industrial sites and enable next-generation manufacturing. By combining lifecycle optimization, regulatory alignment, and mission-critical cybersecurity and physical protection, the company delivers resilient, high-performance facilities designed for sustained operations in complex and contested environments. Its program advisory expertise, including long-standing support to the Department of Energy and the Department of War, helps translate evolving mission requirements into executable infrastructure investments that strengthen the full industrial ecosystem from production through distribution.

Parsons also delivers the critical infrastructure that powers and sustains industrial capacity, including energy and microgrid solutions and industrial water and wastewater systems. In addition, the company is also advancing nuclear energy solutions critical to powering next-generation industrial capacity and strengthening energy resilience. The integrated energy capabilities are delivered across the full lifecycle, supporting both national security missions and commercial energy infrastructure, including energy-intensive industries such as advanced manufacturing and data centers.

These capabilities extend across North America, the Middle East, and other key markets, including Canada, where Parsons supports infrastructure and industrial development aligned with national growth and resource priorities. This global reach, combined with deep technical expertise, positions Parsons to deliver consistent, high-impact outcomes across diverse operational environments.

Demand for industrial base modernization continues to accelerate, driven by geopolitical competition, supply chain vulnerabilities, and significant government investment in munitions production, advanced manufacturing, and critical infrastructure. Parsons is directly aligned with these priorities, helping customers respond to urgent operational needs while building long-term resilience.

With decades of experience delivering complex industrial and infrastructure programs, Parsons continues to enable the next generation of scalable, resilient, and secure industrial capacity, delivering capability at the speed and scale today’s missions demand.

To learn more about Parsons’ industrial base modernization capabilities, visit parsons.com/industrial-base-modernization/ and parsons.com/manufacturing/.

About Parsons 

Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact. 

Forward-Looking Statements 

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs and assumptions, and are not guarantees of future performance. Forward-looking statements are inherently subject to uncertainties, risks, changes in circumstances, trends and factors that are difficult to predict, many of which are outside of our control. Accordingly, actual performance, results and events may vary materially from those indicated in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future performance, results or events. Numerous factors could cause actual future performance, results and events to differ materially from those indicated in the forward-looking statements, including, among others: any issue that compromises our relationships with the U.S. federal government or its agencies or other state, local or foreign governments or agencies; any issues that damage our professional reputation; changes in governmental priorities that shift expenditures away from agencies or programs that we support; our dependence on long-term government contracts, which are subject to the government’s budgetary approval process; the size of our addressable markets and the amount of government spending on private contractors; failure by us or our employees to obtain and maintain necessary security clearances or certifications; failure to comply with numerous laws and regulations; changes in government procurement, contract or other practices or the adoption by governments of new laws, rules, regulations and programs in a manner adverse to us; the termination or nonrenewal of our government contracts, particularly our contracts with the U.S. federal government; our ability to compete effectively in the competitive bidding process and delays, contract terminations or cancellations caused by competitors’ protests of major contract awards received by us; our ability to generate revenue under certain of our contracts; any inability to attract, train or retain employees with the requisite skills, experience and security clearances; the loss of members of senior management or failure to develop new leaders; misconduct or other improper activities from our employees or subcontractors; our ability to realize the full value of our backlog and the timing of our receipt of revenue under contracts included in backlog; changes in the mix of our contracts and our ability to accurately estimate or otherwise recover expenses, time and resources for our contracts; changes in estimates used in recognizing revenue; internal system or service failures and security breaches; and inherent uncertainties and potential adverse developments in legal proceedings, including litigation, audits, reviews and investigations, which may result in materially adverse judgments, settlements or other unfavorable outcomes. These factors are not exhaustive and additional factors could adversely affect our business and financial performance. For a discussion of additional factors that could materially adversely affect our business and financial performance, see the factors included under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the Securities and Exchange Commission. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. We assume no obligation to update any forward-looking statement made in this press release that becomes untrue because of subsequent events, new information or otherwise, except to the extent we are required to do so by law. 

Media Contact:
Bernadette Miller
+1 980.253.9781
[email protected]

Investor Relations Contact:
Dave Spille
+1 703.775.6191
[email protected]

Andra AP fonden lifted its position in shares of Amphenol Corporation (NYSE:APH – Free Report) by 96.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 239,588 shares of the electronics maker’s stock after buying an additional 117,453 shares during the period. Andra AP fonden’s holdings in Amphenol were worth $30,272,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Amphenol by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 126,553,498 shares of the electronics maker’s stock valued at $17,102,440,000 after buying an additional 1,322,682 shares during the period. J. Stern & Co. LLP lifted its holdings in shares of Amphenol by 9,435.8% during the 4th quarter. J. Stern & Co. LLP now owns 76,769,791 shares of the electronics maker’s stock valued at $10,374,670,000 after acquiring an additional 75,964,718 shares in the last quarter. State Street Corp boosted its position in Amphenol by 1.6% during the 4th quarter. State Street Corp now owns 56,913,598 shares of the electronics maker’s stock worth $7,705,440,000 after purchasing an additional 888,526 shares during the period. JPMorgan Chase & Co. boosted its position in Amphenol by 102.7% during the 4th quarter. JPMorgan Chase & Co. now owns 34,325,148 shares of the electronics maker’s stock worth $4,638,701,000 after purchasing an additional 17,387,536 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Amphenol by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 30,318,652 shares of the electronics maker’s stock valued at $4,087,372,000 after purchasing an additional 748,813 shares in the last quarter. Institutional investors and hedge funds own 97.01% of the company’s stock.

Amphenol Trading Down 0.5% NYSE:APH opened at $150.50 on Tuesday. The stock has a market cap of $185.15 billion, a price-to-earnings ratio of 43.25, a price-to-earnings-growth ratio of 1.29 and a beta of 1.24. Amphenol Corporation has a one year low of $95.19 and a one year high of $178.52. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.26 and a current ratio of 1.71. The business’s 50-day simple moving average is $150.36 and its 200 day simple moving average is $144.16.

Amphenol (NYSE:APH – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The electronics maker reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.11. The firm had revenue of $7.62 billion during the quarter, compared to analyst estimates of $7.08 billion. Amphenol had a return on equity of 37.44% and a net margin of 17.24%.Amphenol’s quarterly revenue was up 58.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.63 EPS. Amphenol has set its Q2 2026 guidance at 1.140-1.160 EPS. As a group, sell-side analysts predict that Amphenol Corporation will post 4.87 earnings per share for the current fiscal year.

Amphenol Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 15th. Shareholders of record on Tuesday, June 23rd were issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Tuesday, June 23rd. Amphenol’s dividend payout ratio (DPR) is currently 28.74%.

Insider Buying and Selling at Amphenol In other news, CEO Richard Adam Norwitt sold 17,500 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $143.21, for a total value of $2,506,175.00. Following the sale, the chief executive officer owned 1,927,507 shares in the company, valued at approximately $276,038,277.47. This represents a 0.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders have sold 130,775 shares of company stock valued at $18,709,350. 1.42% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In A number of research analysts have commented on the company. JPMorgan Chase & Co. boosted their price objective on Amphenol from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Robert W. Baird set a $177.00 target price on Amphenol in a research note on Thursday, April 30th. Seaport Research Partners reissued a “buy” rating and set a $215.00 price target on shares of Amphenol in a research report on Thursday, April 30th. TD Cowen restated a “hold” rating and issued a $175.00 price target (up from $135.00) on shares of Amphenol in a report on Monday, July 13th. Finally, Jefferies Financial Group increased their price objective on shares of Amphenol from $165.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Fourteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Amphenol presently has a consensus rating of “Moderate Buy” and a consensus target price of $186.00.

Get Our Latest Stock Report on APH

Amphenol Company Profile (Free Report)

Amphenol Corporation (NYSE: APH) is a leading global manufacturer of electronic and fiber optic connectors, interconnect systems, and related components. The company designs, engineers and produces a broad range of products including electrical connectors, cable assemblies, fiber optic solutions, sensors, antennas and electromechanical devices used to transfer power, signal and data across complex systems. Its product portfolio spans ruggedized connectors for harsh environments to high-speed solutions for data centers and telecommunications networks.

Amphenol serves a diverse set of end markets, including automotive, broadband and telecom, data communications, mobile devices, industrial, energy, and military/aerospace.

Featured Articles Five stocks we like better than Amphenol The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding APH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphenol Corporation (NYSE:APH – Free Report).

Receive News & Ratings for Amphenol Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphenol and related companies with MarketBeat.com's FREE daily email newsletter.

Samsung’s hybrid bonding technology is expected to be used in NVIDIA’s next-generation Feynman AI accelerator, with the chip featuring custom HBM.

Samsung Electronics has commenced construction of a Die-to-Wafer (D2W) hybrid bonding production line at its P5 plant in Pyeongtaek, targeting advanced packaging for next-generation High Bandwidth Memory (HBM) and logic semiconductors. Samsung’s top pick for core equipment suppliers is Dutch firm Besi; the company plans to procure around 50 hybrid bonding machines, each priced at roughly 6 billion won (about $4.3 million) — twice the cost of competing products. However, negotiations have moved slowly due to Samsung’s demand for custom modifications to the machine architecture, and Besi, which also supplies TSMC and Micron, is cautious about modifying equipment exclusively for Samsung. Samsung is simultaneously evaluating local alternatives: its subsidiary SEMES has completed development of D2W hybrid bonding machines and delivered samples for validation earlier this year. Hanwha Semitech finished developing its second-generation "SHB2 Nano" in February, and sent samples to SK Hynix in April. Its cluster system integrating Equipment Front End Module (EFEM), plasma activation, and cleaning modules offers distinct competitive advantages. This technology replaces traditional thermocompression bonding with hybrid copper bonding, enabling direct bonding of copper and dielectric materials and drastically shortening interconnect lengths. Its core application is custom HBM: vertically stacking HBM DRAM layers directly on logic dies containing customers’ computing circuits and intellectual property (IP) to form 3D system-in-package (SiP) solutions. Citrini analyst Jukan stated that hybrid bonding is expected to be used in NVIDIA’s next-generation AI accelerator Feynman, which will adopt custom HBM, with the technology’s deployment timeline "pushed back from HBM4E". Samsung’s internal projections indicate large-scale commercialization will not be achieved until around 2029–2030, a timeline that aligns with NVIDIA’s expected window for Feynman.

5 minutes ago

Trump could impose new tariffs on dozens of countries as early as this week.

According to the Financial Times, US President Donald Trump will impose new tariffs on dozens of countries as early as this week.

5 minutes ago

TrendForce forecasts that the NAND flash memory supply shortage will ease in 2027.

High-tech industry research firm TrendForce points out that while servers account for over 40% of total NAND flash demand, smartphones and laptops combined still make up nearly 40%, continuing to significantly impact overall demand. On the inventory front, memory manufacturers’ stock levels remain relatively low. Though module manufacturers’ inventories have risen due to weak consumer market conditions, inventories held by other buyers stay controllable. Taking all these factors into account, TrendForce projects the NAND flash bit supply-demand gap will hold at 4%–5% in 2026, signaling ongoing supply shortages. However, the gap is expected to turn positive in the second half of 2027, alleviating supply tightness.

5 minutes ago

China's National Supercomputing Internet recently launched the API call service for the Kimi K3 model.

According to monitoring by Beating (Dongcha), China’s National Supercomputing Internet recently launched the Kimi K3 model API calling service. Enterprises and developers can quickly access large language model (LLM) capabilities without cumbersome environment configuration. The API is compatible with OpenAI and Anthropic interface specifications, enabling fast, low-cost deployment of diverse AI applications. Additionally, the Supercomputing Internet has rolled out the 100,000-Creation Plan, providing one-stop Model as a Service (MaaS) offerings.

5 minutes ago

Samsung reportedly starts supplying V10 NAND flash memory to Nvidia.

Samsung Electronics is expanding its collaboration with Nvidia in the NAND flash memory sector. Industry sources revealed that Samsung has built V-NAND production capacity exceeding 100,000 wafers per month and is mass-producing its 10th-generation V10 products for supply to Nvidia. It is reported that Samsung has allocated approximately 60% of its V-NAND production capacity to V9 flash memory, a move aimed at meeting Nvidia’s demand for NAND for its CMX products set to launch in the second half of the year. In addition, Samsung has started trial production of 500-layer V11 flash memory; the trial production began earlier this year, and the company plans to double the related output in the second half of the year.

5 minutes ago

Serenity analyzes AMD’s MI500 and CPO roadmap: A clear commitment to optical interconnects would be an industry-wide positive development.

AMD will host its Advancing AI event in San Francisco from July 22 to 23, where more details about its MI500 series GPUs and scale-up Co-Packaged Optics (CPO) roadmap are set to be unveiled. In response to community queries, Serenity noted that if AMD explicitly commits to a CPO solution and discloses its optical engine supplier at the event, it will be a major positive for the entire CPO ecosystem—meaning NVIDIA is no longer the sole player driving the optical interconnect transition. Jefferies analyst Blayne Curtis currently expects AMD to partner with Astera Labs on UAL and Broadcom on ESUN, but the key watchpoint is whether AMD will officially shift to a CPO-based scale-up design and who will supply the optical engine. Serenity added that a clearer supply chain picture will only emerge after the event (held Wednesday and Thursday), so conclusions are premature for now. For Sivers, its supply chain ties to AMD’s CPO plans can only be inferred indirectly at present: first, GlobalFoundries (GF) is rumored to be involved in AMD’s MI500 CPO work, and Sivers is GF’s reference laser supplier; second, AMD has previously invested in Ayar Labs. If AMD confirms at the event that it will use Ayar Labs or GF’s SCALE as the optical engine for the MI500 CPO, it will be a massive boost for Sivers, which holds a core role as an upstream laser and reference laser supplier in both potential paths. The upcoming MI500 is expected to adopt a native UAL scale-up architecture, supporting 256 GPUs per rack and interconnected via optical links. Sivers has been steadily securing positions across multiple tech tracks this year, including CPO, pluggable optical modules, and silicon photonics. If AMD’s event confirms Sivers’ indirect entry into the supply chain, it will further validate the company’s full-scenario layout logic in the optical interconnect sector.

5 minutes ago

515 Million NIGHT Tokens Drained in Bridge AttackWanchain's bridge connecting Cardano to BNB Chain was exploited on July 21, 2026, with approximately 515.2 million $NIGHT tokens drained from the bridge treasury. The stolen tokens were worth roughly $13 million at pre-exploit prices. CoinGecko data showed the token trading near $0.0186 after the incident, placing the value of 515 million NIGHT closer to $9 million to $10 million at prevailing prices.

The incident unfolded in just four rapid transactions over an eight-minute window. BlockSec Phalcon traced the attacker's redeemer back to a legitimate BSC transaction that authorized only around 3,110 NIGHT, with the same signature then reused on Cardano to extract more than 203 million NIGHT through field-boundary ambiguity in the raw-concatenated hash. The attacker funneled stolen tokens into a primary wallet on Cardano before aggressively liquidating roughly 90% of the haul through DEX swaps and DeFi protocols.

Validator Flaw at the Root of the ExploitBlockSec's monitoring revealed that the attack exploited a vulnerability in the TreasuryCheck validator's signature message encoding. The issue arose from the raw concatenation of 14 variable-length redemption fields without delimiters, allowing different field combinations to produce identical byte strings and reuse the same hash and signature. BlockSec confirmed the vulnerability by analyzing on-chain Plutus V2 bytecode and decoding the attack transaction's redemption data, noting that use of Sha3_256(SerialiseData(...)) could have prevented this by providing clear CBOR-encoded field boundaries.

Wanchain confirmed it was aware of an incident affecting the Cardano BNB Chain bridge, resulting in the withdrawal of NIGHT tokens from the bridge contract on Cardano, and said the bridge was taken offline while the team investigates. Midnight said its core network remained secure, describing the incident as isolated to bridge infrastructure.

NIGHT is Midnight's native governance token and also generates DUST, the network resource used for transactions and smart contract execution. Midnight operates as a privacy-focused Cardano partner chain with a dual-token economic model, and launched its mainnet in March 2026. NIGHT sold off sharply as reports of the bridge incident spread, falling more than 30% within 24 hours to a record low near $0.016.

Wanchain originally launched cross-chain support for NIGHT between Cardano and BNB Chain in December 2025. The latest bridge incident has brought renewed attention to the risks created when native assets move through third-party infrastructure.

Sources:
Crypto.news: Wanchain Cardano bridge exploit drains 515M NIGHT
CryptoTimes: Wanchain Cardano Bridge Exploited
Phemex News: Wanchain Cardano Bridge Hacked

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. lifted its holdings in shares of Datadog, Inc. (NASDAQ:DDOG – Free Report) by 15.0% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 140,788 shares of the company’s stock after buying an additional 18,322 shares during the period. Amova Asset Management Americas Inc.’s holdings in Datadog were worth $16,616,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC bought a new stake in shares of Datadog during the fourth quarter worth $209,000. Bison Wealth LLC bought a new position in shares of Datadog in the 4th quarter valued at $228,000. Empowered Funds LLC boosted its holdings in shares of Datadog by 7.0% during the 1st quarter. Empowered Funds LLC now owns 10,313 shares of the company’s stock valued at $1,023,000 after acquiring an additional 672 shares in the last quarter. Geneos Wealth Management Inc. boosted its holdings in shares of Datadog by 17.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 769 shares of the company’s stock valued at $76,000 after acquiring an additional 115 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in Datadog during the 2nd quarter worth $509,000. Institutional investors and hedge funds own 78.29% of the company’s stock.

Insider Activity In other news, Director Michael James Callahan sold 112,500 shares of the business’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $231.60, for a total transaction of $26,055,000.00. Following the completion of the sale, the director directly owned 14,996 shares of the company’s stock, valued at $3,473,073.60. The trade was a 88.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO David M. Obstler sold 75,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $231.69, for a total transaction of $17,376,750.00. Following the completion of the transaction, the chief financial officer directly owned 434,591 shares in the company, valued at approximately $100,690,388.79. The trade was a 14.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 1,439,533 shares of company stock valued at $323,367,430. Corporate insiders own 6.48% of the company’s stock.

Datadog News Roundup Here are the key news stories impacting Datadog this week:

Positive Sentiment: JMP Securities raised its price target to $311 from $225 and kept an Outperform-style rating, saying infrastructure software looks stronger than applications and that Datadog has been a standout performer in its coverage. Why Datadog (DDOG) Stock Is Trading Up Today Positive Sentiment: Wells Fargo increased its target to $295 from $230 and reiterated an Overweight rating, suggesting more upside from current levels. Datadog Price Target Raised by Wells Fargo Positive Sentiment: Oppenheimer lifted its target to $300 from $220 and maintained an Outperform rating, adding to the wave of upbeat analyst calls. Datadog Price Target Raised by Oppenheimer Positive Sentiment: Another report said Citizens JMP raised Datadog’s target to $311 from $225, implying further confidence in the stock’s run after its strong year-to-date performance. Datadog Price Target Raised by Citizens JMP Neutral Sentiment: One comparison piece argued that Penguin is the better AI infrastructure buy than Datadog because of faster growth, AI momentum, and a lower valuation, which may temper enthusiasm but does not appear to be a direct catalyst. PENG vs. DDOG: Which AI Infrastructure Stock Is the Better Buy Now? Datadog Stock Up 1.7% Shares of NASDAQ:DDOG opened at $263.20 on Tuesday. Datadog, Inc. has a 1 year low of $98.01 and a 1 year high of $278.70. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.40 and a quick ratio of 3.40. The business’s 50-day moving average is $237.89 and its 200-day moving average is $165.62. The company has a market capitalization of $93.69 billion, a price-to-earnings ratio of 692.65, a P/E/G ratio of 26.30 and a beta of 1.54.

Datadog (NASDAQ:DDOG – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.51 by $0.09. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $960.12 million. Datadog had a return on equity of 4.83% and a net margin of 3.69%.The firm’s revenue was up 32.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.46 earnings per share. Datadog has set its FY 2026 guidance at 2.360-2.440 EPS and its Q2 2026 guidance at 0.570-0.590 EPS. Equities research analysts predict that Datadog, Inc. will post 0.64 earnings per share for the current year.

Wall Street Analyst Weigh In A number of equities analysts have issued reports on DDOG shares. Morgan Stanley raised Datadog from an “overweight” rating to an “overweight” rating in a report on Monday, June 15th. Craig Hallum started coverage on Datadog in a report on Monday, June 15th. They set a “buy” rating on the stock. Monness Crespi & Hardt upped their price objective on Datadog from $255.00 to $270.00 in a research note on Thursday, May 7th. Stifel Nicolaus set a $305.00 price objective on shares of Datadog in a report on Thursday, May 7th. Finally, Wedbush started coverage on shares of Datadog in a report on Monday, June 15th. They set a “neutral” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, forty have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.80.

Get Our Latest Research Report on DDOG

Datadog Company Profile (Free Report)

Datadog (NASDAQ: DDOG) is a cloud-based monitoring and observability platform that helps organizations monitor, troubleshoot and secure their applications and infrastructure at scale. Its software-as-a-service offering collects and analyzes metrics, traces and logs from servers, containers, cloud services and applications to provide real-time visibility into system performance and health. Datadog’s platform is widely used by engineering, operations and security teams to reduce downtime, accelerate incident response and improve application reliability.

The company’s product suite includes infrastructure monitoring, application performance monitoring (APM), log management, real user monitoring (RUM), synthetic monitoring and network performance monitoring, along with security-focused products such as security monitoring and cloud SIEM.

Recommended Stories Five stocks we like better than Datadog The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Datadog Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Datadog and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAmova Asset Management Americas Inc. Has $17.18 Million Holdings in Pony AI Inc. – Sponsored ADR $PONY

NEXT HEADLINE »Schrodinger, Inc. $SDGR Shares Purchased by Amova Asset Management Americas Inc.

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 5.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,853,875 shares of the company’s stock after selling 104,236 shares during the quarter. CRISPR Therapeutics comprises approximately 1.2% of Amova Asset Management Americas Inc.’s holdings, making the stock its 26th biggest holding. Amova Asset Management Americas Inc. owned approximately 1.92% of CRISPR Therapeutics worth $88,189,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in CRSP. Hollencrest Capital Management increased its holdings in shares of CRISPR Therapeutics by 249.9% during the 1st quarter. Hollencrest Capital Management now owns 1,312 shares of the company’s stock worth $62,000 after buying an additional 937 shares during the last quarter. KBC Group NV boosted its holdings in CRISPR Therapeutics by 3,999.9% in the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock valued at $5,558,000 after acquiring an additional 113,997 shares during the last quarter. Swiss National Bank grew its position in CRISPR Therapeutics by 5.1% during the first quarter. Swiss National Bank now owns 169,700 shares of the company’s stock valued at $8,073,000 after acquiring an additional 8,200 shares during the period. Allspring Global Investments Holdings LLC grew its position in CRISPR Therapeutics by 11.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,932 shares of the company’s stock valued at $290,000 after acquiring an additional 605 shares during the period. Finally, Independent Financial Group LLC acquired a new stake in CRISPR Therapeutics during the first quarter worth about $292,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at CRISPR Therapeutics In related news, insider Naimish Patel sold 3,786 shares of CRISPR Therapeutics stock in a transaction on Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the sale, the insider owned 19,357 shares of the company’s stock, valued at $1,076,636.34. The trade was a 16.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by company insiders.

CRISPR Therapeutics Stock Down 1.7% NASDAQ CRSP opened at $46.99 on Tuesday. The company has a quick ratio of 17.96, a current ratio of 17.97 and a debt-to-equity ratio of 0.32. CRISPR Therapeutics AG has a fifty-two week low of $44.12 and a fifty-two week high of $78.48. The business has a 50 day moving average price of $52.96 and a two-hundred day moving average price of $52.88. The stock has a market cap of $4.53 billion, a PE ratio of -7.55 and a beta of 1.71.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. The firm had revenue of $1.46 million for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -4.9 EPS for the current fiscal year.

Analysts Set New Price Targets A number of equities analysts have recently commented on the company. Wall Street Zen downgraded CRISPR Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, July 5th. Citizens Jmp reissued a “market outperform” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday. Evercore reaffirmed an “outperform” rating and set a $76.00 price target on shares of CRISPR Therapeutics in a research report on Monday, May 11th. Finally, UBS Group set a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 12th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $67.78.

Check Out Our Latest Report on CRISPR Therapeutics

About CRISPR Therapeutics (Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

Featured Articles Five stocks we like better than CRISPR Therapeutics The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAlTi Global Inc. Sells 1,847 Shares of Vanguard Small-Cap ETF $VB

NEXT HEADLINE »10x Genomics $TXG Shares Sold by Amova Asset Management Americas Inc.

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC lessened its holdings in shares of Wintrust Financial Corporation (NASDAQ:WTFC – Free Report) by 22.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 147,086 shares of the bank’s stock after selling 43,401 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.22% of Wintrust Financial worth $20,601,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of WTFC. Norges Bank bought a new stake in Wintrust Financial during the fourth quarter valued at approximately $111,924,000. Wellington Management Group LLP bought a new position in shares of Wintrust Financial in the 3rd quarter worth $90,187,000. Artemis Investment Management LLP bought a new position in shares of Wintrust Financial in the 4th quarter worth $59,287,000. Vaughan Nelson Investment Management L.P. purchased a new stake in shares of Wintrust Financial during the 1st quarter valued at $34,272,000. Finally, Balyasny Asset Management L.P. raised its position in shares of Wintrust Financial by 491.6% during the 4th quarter. Balyasny Asset Management L.P. now owns 254,329 shares of the bank’s stock valued at $35,560,000 after buying an additional 211,338 shares in the last quarter. Hedge funds and other institutional investors own 93.48% of the company’s stock.

Wintrust Financial Stock Performance Wintrust Financial stock opened at $163.66 on Tuesday. The company has a quick ratio of 0.97, a current ratio of 0.98 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $11.04 billion, a PE ratio of 13.72 and a beta of 0.84. The firm has a fifty day simple moving average of $155.48 and a two-hundred day simple moving average of $149.06. Wintrust Financial Corporation has a twelve month low of $119.61 and a twelve month high of $167.21.

Wintrust Financial (NASDAQ:WTFC – Get Free Report) last announced its quarterly earnings data on Monday, July 20th. The bank reported $3.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.15 by $0.15. The firm had revenue of $961.41 million for the quarter, compared to analysts’ expectations of $735.36 million. Wintrust Financial had a return on equity of 13.15% and a net margin of 20.11%.During the same period last year, the firm earned $2.78 earnings per share. Research analysts expect that Wintrust Financial Corporation will post 13.03 EPS for the current year.

Wall Street Analyst Weigh In WTFC has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating and issued a $188.00 target price (up from $184.00) on shares of Wintrust Financial in a research report on Wednesday, April 22nd. Weiss Ratings restated a “buy (b)” rating on shares of Wintrust Financial in a research report on Monday, June 29th. TD Cowen lifted their price target on Wintrust Financial from $173.00 to $176.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. DA Davidson reiterated a “buy” rating and issued a $185.00 price objective on shares of Wintrust Financial in a report on Tuesday, June 30th. Finally, UBS Group reiterated a “neutral” rating and set a $170.00 price objective on shares of Wintrust Financial in a research report on Tuesday, July 7th. Ten research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $174.92.

Read Our Latest Stock Analysis on Wintrust Financial

Insider Buying and Selling In related news, CFO David L. Stoehr sold 3,020 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $150.45, for a total transaction of $454,359.00. Following the completion of the sale, the chief financial officer directly owned 13,213 shares in the company, valued at $1,987,895.85. This represents a 18.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Suzet M. Mckinney sold 500 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $148.96, for a total transaction of $74,480.00. Following the sale, the director directly owned 3,303 shares of the company’s stock, valued at $492,014.88. The trade was a 13.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,099 shares of company stock worth $1,954,386 in the last ninety days. 1.24% of the stock is owned by insiders.

Wintrust Financial Profile (Free Report)

Wintrust Financial Corporation is a Chicago‐area bank holding company headquartered in Rosemont, Illinois. Through its primary subsidiary, Wintrust Bank, the company operates a network of community banks serving metropolitan Chicago and select markets in southeastern Wisconsin. These locally branded banks provide personalized commercial and consumer banking solutions tailored to small and mid‐size businesses, professionals, and individual clients.

The firm’s core offerings include deposit products, commercial and residential lending, treasury management, and mortgage banking services.

Further Reading Five stocks we like better than Wintrust Financial The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Wintrust Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wintrust Financial and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAlpha Zero LLC Has $10.73 Million Position in Invesco S&P 500 Momentum ETF $SPMO

NEXT HEADLINE »Schwab US Large-Cap ETF $SCHX Holdings Boosted by Alpha Zero LLC

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden boosted its position in shares of Arista Networks, Inc. (NYSE:ANET – Free Report) by 22.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 250,000 shares of the technology company’s stock after purchasing an additional 46,000 shares during the quarter. Andra AP fonden’s holdings in Arista Networks were worth $30,695,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Intrua Financial LLC lifted its stake in shares of Arista Networks by 2.7% in the first quarter. Intrua Financial LLC now owns 2,307 shares of the technology company’s stock worth $283,000 after buying an additional 61 shares in the last quarter. NBT Bank N A NY increased its position in shares of Arista Networks by 37.2% during the first quarter. NBT Bank N A NY now owns 247 shares of the technology company’s stock valued at $30,000 after acquiring an additional 67 shares in the last quarter. Hoxton Planning & Management LLC raised its holdings in Arista Networks by 4.1% in the 1st quarter. Hoxton Planning & Management LLC now owns 1,744 shares of the technology company’s stock worth $214,000 after acquiring an additional 68 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its position in Arista Networks by 0.4% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 16,085 shares of the technology company’s stock valued at $2,133,000 after acquiring an additional 70 shares in the last quarter. Finally, Y.D. More Investments Ltd lifted its position in Arista Networks by 8.7% in the 1st quarter. Y.D. More Investments Ltd now owns 870 shares of the technology company’s stock valued at $107,000 after acquiring an additional 70 shares in the last quarter. 82.47% of the stock is currently owned by institutional investors.

Insider Transactions at Arista Networks In related news, CEO Jayshree Ullal sold 234,578 shares of the business’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $187.18, for a total value of $43,908,310.04. Following the sale, the chief executive officer directly owned 5,134,207 shares in the company, valued at approximately $961,020,866.26. The trade was a 4.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Andreas Bechtolsheim sold 240,000 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $162.67, for a total value of $39,040,800.00. Following the transaction, the insider directly owned 182,043,048 shares of the company’s stock, valued at approximately $29,612,942,618.16. The trade was a 0.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 2,692,983 shares of company stock valued at $452,119,385. 2.70% of the stock is owned by company insiders.

Arista Networks Stock Performance Shares of NYSE:ANET opened at $169.17 on Tuesday. The firm has a market cap of $213.02 billion, a price-to-earnings ratio of 57.94, a P/E/G ratio of 2.59 and a beta of 1.60. The firm has a fifty day moving average price of $162.41 and a 200 day moving average price of $147.60. Arista Networks, Inc. has a fifty-two week low of $106.99 and a fifty-two week high of $189.82.

Arista Networks (NYSE:ANET – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The technology company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.06. The company had revenue of $2.71 billion for the quarter, compared to the consensus estimate of $2.62 billion. Arista Networks had a net margin of 38.32% and a return on equity of 30.10%. Arista Networks’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.65 EPS. Arista Networks has set its Q2 2026 guidance at 0.880-0.880 EPS. As a group, research analysts predict that Arista Networks, Inc. will post 3.28 earnings per share for the current year.

Analyst Ratings Changes ANET has been the subject of several recent analyst reports. Wolfe Research restated an “outperform” rating and issued a $175.00 price target on shares of Arista Networks in a research note on Wednesday, June 10th. Citigroup reduced their price objective on Arista Networks from $176.00 to $173.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Truist Financial set a $175.00 target price on shares of Arista Networks in a research note on Wednesday, May 6th. Barclays reaffirmed an “overweight” rating and set a $195.00 price target (up from $184.00) on shares of Arista Networks in a report on Thursday, May 7th. Finally, UBS Group reaffirmed a “buy” rating and issued a $187.00 target price (up from $177.00) on shares of Arista Networks in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $188.95.

Check Out Our Latest Research Report on ANET

Arista Networks Profile (Free Report)

Arista Networks, Inc is a technology company that designs and sells cloud networking solutions for large-scale data centers and enterprise environments. The company is best known for its high-performance switching and routing platforms, which are used to build scalable, low-latency networks for cloud service providers, internet companies, financial services, telecommunications, and enterprise IT. Arista’s offerings emphasize programmability, automation and telemetry to support modern, software-driven network architectures.

Central to Arista’s product portfolio is its Extensible Operating System (EOS), a modular network operating system that provides consistent programmability, stateful control and advanced visibility across the company’s hardware platforms.

Featured Articles Five stocks we like better than Arista Networks The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Arista Networks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arista Networks and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Has $43.84 Million Stock Holdings in Merck & Co., Inc. $MRK

NEXT HEADLINE »Procter & Gamble Company (The) $PG Shares Purchased by Andra AP fonden

Allspring Global Investments Holdings LLC cut its stake in Sempra Energy (NYSE:SRE – Free Report) by 6.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 212,027 shares of the utilities provider’s stock after selling 14,131 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Sempra Energy were worth $20,654,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in SRE. Vanguard Group Inc. grew its stake in Sempra Energy by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 76,734,070 shares of the utilities provider’s stock valued at $6,774,907,000 after acquiring an additional 1,008,476 shares in the last quarter. State Street Corp lifted its stake in Sempra Energy by 5.2% in the 4th quarter. State Street Corp now owns 36,810,449 shares of the utilities provider’s stock worth $3,273,460,000 after purchasing an additional 1,824,280 shares in the last quarter. Morgan Stanley boosted its holdings in Sempra Energy by 17.0% in the 4th quarter. Morgan Stanley now owns 22,330,091 shares of the utilities provider’s stock valued at $1,971,524,000 after purchasing an additional 3,250,783 shares during the period. Geode Capital Management LLC grew its position in shares of Sempra Energy by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 14,298,845 shares of the utilities provider’s stock valued at $1,256,592,000 after purchasing an additional 116,554 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Sempra Energy by 16.6% during the 4th quarter. JPMorgan Chase & Co. now owns 12,163,523 shares of the utilities provider’s stock valued at $1,073,918,000 after purchasing an additional 1,735,516 shares in the last quarter. Hedge funds and other institutional investors own 89.65% of the company’s stock.

Analyst Upgrades and Downgrades SRE has been the topic of a number of research analyst reports. BMO Capital Markets decreased their target price on Sempra Energy from $105.00 to $103.00 and set an “outperform” rating on the stock in a research note on Monday, May 11th. Wall Street Zen lowered Sempra Energy from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. TD Cowen initiated coverage on shares of Sempra Energy in a research report on Wednesday, July 8th. They issued a “buy” rating on the stock. Morgan Stanley reiterated an “overweight” rating and set a $105.00 target price on shares of Sempra Energy in a research report on Wednesday, June 24th. Finally, Barclays cut their price target on shares of Sempra Energy from $105.00 to $103.00 and set an “overweight” rating for the company in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $104.08.

Get Our Latest Analysis on SRE

Sempra Energy Trading Down 1.6% SRE stock opened at $90.75 on Tuesday. The company has a market capitalization of $59.33 billion, a PE ratio of 30.76, a price-to-earnings-growth ratio of 2.22 and a beta of 0.56. Sempra Energy has a one year low of $77.87 and a one year high of $101.04. The company’s 50 day moving average price is $91.90 and its two-hundred day moving average price is $92.33. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.66 and a current ratio of 1.69.

Sempra Energy (NYSE:SRE – Get Free Report) last released its earnings results on Thursday, May 7th. The utilities provider reported $1.51 EPS for the quarter, meeting the consensus estimate of $1.51. The company had revenue of $3.65 billion for the quarter, compared to analyst estimates of $4.10 billion. Sempra Energy had a net margin of 14.31% and a return on equity of 8.20%. The firm’s quarterly revenue was down 3.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.44 EPS. Sempra Energy has set its FY 2027 guidance at 5.100-5.700 EPS and its FY 2026 guidance at 4.870-5.370 EPS. As a group, analysts predict that Sempra Energy will post 5.12 earnings per share for the current fiscal year.

Sempra Energy Dividend Announcement The company also recently declared a quarterly dividend, which was paid on Wednesday, July 15th. Shareholders of record on Thursday, June 25th were issued a $0.6575 dividend. This represents a $2.63 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Thursday, June 25th. Sempra Energy’s dividend payout ratio (DPR) is 89.15%.

Insider Activity at Sempra Energy In related news, EVP Caroline Ann Winn sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $90.55, for a total transaction of $724,400.00. Following the completion of the transaction, the executive vice president owned 25,164 shares in the company, valued at $2,278,600.20. This represents a 24.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Diana L. Day sold 3,300 shares of the firm’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $92.13, for a total transaction of $304,029.00. Following the completion of the sale, the insider owned 22,870 shares of the company’s stock, valued at $2,107,013.10. This trade represents a 12.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,900 shares of company stock worth $1,261,207 in the last 90 days. Company insiders own 0.31% of the company’s stock.

Sempra Energy Profile (Free Report)

Sempra Energy is a San Diego–based energy infrastructure company that develops, owns and operates businesses delivering electricity and natural gas. Its operations include regulated utility services that provide electric and gas distribution to residential, commercial and industrial customers, as well as non‑regulated infrastructure businesses that develop and manage large-scale energy assets.

The company’s product and service portfolio spans electricity and natural gas delivery, transmission and storage, liquefied natural gas (LNG) facilities, power generation and electric transmission projects.

Further Reading Five stocks we like better than Sempra Energy The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding SRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sempra Energy (NYSE:SRE – Free Report).

Receive News & Ratings for Sempra Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sempra Energy and related companies with MarketBeat.com's FREE daily email newsletter.

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. increased its holdings in shares of DoorDash, Inc. (NASDAQ:DASH – Free Report) by 6.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 252,253 shares of the company’s stock after acquiring an additional 15,929 shares during the quarter. Amova Asset Management Americas Inc. owned approximately 0.06% of DoorDash worth $37,861,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. CYBER HORNET ETFs LLC boosted its position in DoorDash by 6.5% during the 4th quarter. CYBER HORNET ETFs LLC now owns 979 shares of the company’s stock valued at $222,000 after purchasing an additional 60 shares during the period. Vise Technologies Inc. grew its position in shares of DoorDash by 1.8% during the fourth quarter. Vise Technologies Inc. now owns 3,517 shares of the company’s stock worth $796,000 after acquiring an additional 63 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of DoorDash by 7.0% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 982 shares of the company’s stock worth $222,000 after acquiring an additional 64 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in shares of DoorDash by 124.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 121 shares of the company’s stock worth $33,000 after acquiring an additional 67 shares during the period. Finally, AXS Investments LLC increased its holdings in shares of DoorDash by 1.3% in the 4th quarter. AXS Investments LLC now owns 5,438 shares of the company’s stock worth $1,232,000 after acquiring an additional 69 shares during the period. Institutional investors own 90.64% of the company’s stock.

Analyst Upgrades and Downgrades Several analysts recently weighed in on DASH shares. Wedbush began coverage on shares of DoorDash in a research report on Thursday, July 16th. They issued a “neutral” rating and a $205.00 price objective on the stock. Jefferies Financial Group raised their price target on shares of DoorDash from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. UBS Group lifted their price target on DoorDash from $206.00 to $214.00 and gave the company a “neutral” rating in a report on Thursday, May 7th. Susquehanna decreased their price objective on DoorDash from $250.00 to $225.00 and set a “positive” rating for the company in a report on Friday, May 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $265.00 target price on shares of DoorDash in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $252.89.

View Our Latest Analysis on DASH

Insider Transactions at DoorDash In other news, Director Andy Fang sold 5,000 shares of the firm’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $180.00, for a total transaction of $900,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ravi Inukonda sold 19,095 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $188.04, for a total value of $3,590,623.80. Following the transaction, the chief financial officer owned 252,443 shares in the company, valued at approximately $47,469,381.72. This trade represents a 7.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 74,927 shares of company stock valued at $13,241,532. Corporate insiders own 5.83% of the company’s stock.

DoorDash Stock Up 2.7% DASH stock opened at $189.02 on Tuesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.43 and a quick ratio of 1.43. The firm has a market capitalization of $82.36 billion, a P/E ratio of 90.01 and a beta of 1.78. DoorDash, Inc. has a 52-week low of $143.30 and a 52-week high of $285.50. The company’s 50 day simple moving average is $170.39 and its 200-day simple moving average is $177.02.

DoorDash (NASDAQ:DASH – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.06. The firm had revenue of $4.04 billion during the quarter, compared to analyst estimates of $4.15 billion. DoorDash had a net margin of 6.29% and a return on equity of 9.58%. The company’s revenue was up 33.1% on a year-over-year basis. During the same quarter last year, the business posted $0.44 EPS. As a group, equities research analysts anticipate that DoorDash, Inc. will post 2.39 EPS for the current year.

DoorDash Profile (Free Report)

DoorDash, Inc operates a technology-driven logistics and food-delivery marketplace that connects consumers, merchants and independent delivery contractors. The company’s core service enables customers to order from local restaurants and retailers through its app and website while DoorDash handles last-mile fulfillment via its network of drivers, known as “Dashers.” Over time the platform has broadened beyond restaurant deliveries to include groceries, convenience items and retail deliveries, positioning DoorDash as a broader on-demand logistics provider for consumer goods.

In addition to its marketplace, DoorDash offers a suite of products and services for consumers and businesses.

Further Reading Five stocks we like better than DoorDash The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for DoorDash Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DoorDash and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAmova Asset Management Americas Inc. Has $24.91 Million Stake in Futu Holdings Limited Sponsored ADR $FUTU

NEXT HEADLINE »Amova Asset Management Americas Inc. Increases Position in CareDx, Inc. $CDNA

Posted by Defense World Staff on Jul 21st, 2026

MGP Ingredients, Inc. (NASDAQ:MGPI – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $20.03 and traded as low as $17.73. MGP Ingredients shares last traded at $18.21, with a volume of 144,624 shares.

Analyst Upgrades and Downgrades Several analysts have weighed in on MGPI shares. TD Cowen lowered their price target on MGP Ingredients from $20.00 to $18.00 and set a “hold” rating on the stock in a report on Friday, June 26th. Weiss Ratings lowered MGP Ingredients from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 4th. Zacks Research upgraded shares of MGP Ingredients from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Finally, Wells Fargo & Company lowered their target price on shares of MGP Ingredients from $24.00 to $21.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $26.50.

Get Our Latest Stock Report on MGP Ingredients

MGP Ingredients Stock Up 2.0% The company has a current ratio of 2.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $389.15 million, a P/E ratio of -1.63 and a beta of 0.46. The company’s fifty day simple moving average is $17.16 and its 200 day simple moving average is $20.03.

MGP Ingredients (NASDAQ:MGPI – Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.11. MGP Ingredients had a negative net margin of 45.70% and a positive return on equity of 7.48%. The firm had revenue of $106.43 million for the quarter, compared to analyst estimates of $105.32 million. During the same quarter in the previous year, the firm posted $0.36 EPS. The company’s revenue for the quarter was down 12.5% compared to the same quarter last year. MGP Ingredients has set its FY 2026 guidance at 1.500-1.800 EPS. Research analysts expect that MGP Ingredients, Inc. will post 1.6 EPS for the current year.

MGP Ingredients Announces Dividend The company also recently announced a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Friday, May 15th were issued a dividend of $0.12 per share. The ex-dividend date was Friday, May 15th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 2.6%. MGP Ingredients’s dividend payout ratio is -4.31%.

Insider Activity In other news, major shareholder Caroline Lux Kaplan sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $17.82, for a total value of $534,600.00. Following the completion of the transaction, the insider owned 500,958 shares in the company, valued at $8,927,071.56. This trade represents a 5.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 31.70% of the company’s stock.

Institutional Inflows and Outflows A number of large investors have recently added to or reduced their stakes in the stock. Tieton Capital Management LLC purchased a new position in MGP Ingredients in the 4th quarter worth about $5,998,000. Pacer Advisors Inc. purchased a new stake in shares of MGP Ingredients during the 4th quarter valued at about $2,278,000. Peregrine Capital Management LLC purchased a new stake in shares of MGP Ingredients during the 4th quarter valued at about $3,606,000. Dana Investment Advisors Inc. bought a new stake in shares of MGP Ingredients in the fourth quarter worth approximately $5,348,000. Finally, Unison Advisors LLC purchased a new position in shares of MGP Ingredients during the fourth quarter valued at approximately $719,000. Hedge funds and other institutional investors own 77.11% of the company’s stock.

About MGP Ingredients (Get Free Report)

MGP Ingredients, Inc (NASDAQ: MGPI) is a leading producer of distilled spirits and specialty ingredient solutions for the food, beverage and consumer products industries. Headquartered in Atchison, Kansas, the company operates two main facilities—its historic Atchison plant, founded in 1941 as Midwest Grain Products, and a modern distillery in Lawrenceburg, Indiana. MGP Ingredients supplies an array of distillation products under its beverage and ingredient segments, serving brand owners, private-label producers and co-packers worldwide.

The beverage segment features a broad portfolio of premium spirits, including bourbon and rye whiskies, vodka, gin and neutral spirits.

See Also Five stocks we like better than MGP Ingredients The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Receive News & Ratings for MGP Ingredients Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MGP Ingredients and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEPedevco (NYSEAMERICAN:PED) Share Price Passes Below 200 Day Moving Average – Here’s Why

NEXT HEADLINE »BNY Mellon Strategic Municipals (NYSE:LEO) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. lowered its stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 13.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,825,585 shares of the company’s stock after selling 583,715 shares during the quarter. Beam Therapeutics makes up 1.3% of Amova Asset Management Americas Inc.’s investment portfolio, making the stock its 24th largest holding. Amova Asset Management Americas Inc. owned about 3.72% of Beam Therapeutics worth $91,164,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of BEAM. Hollencrest Capital Management purchased a new stake in shares of Beam Therapeutics in the 1st quarter valued at approximately $43,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Beam Therapeutics in the 4th quarter worth approximately $47,000. Larson Financial Group LLC grew its position in Beam Therapeutics by 4,370.5% during the 3rd quarter. Larson Financial Group LLC now owns 1,967 shares of the company’s stock worth $48,000 after purchasing an additional 1,923 shares in the last quarter. Van ECK Associates Corp grew its position in Beam Therapeutics by 48.7% during the 3rd quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock worth $52,000 after purchasing an additional 707 shares in the last quarter. Finally, Kestra Advisory Services LLC acquired a new stake in Beam Therapeutics during the 4th quarter valued at $59,000. Institutional investors and hedge funds own 99.68% of the company’s stock.

Insider Buying and Selling In other news, insider Fmr Llc sold 251,488 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $35.26, for a total transaction of $8,867,466.88. Following the transaction, the insider owned 854,583 shares in the company, valued at $30,132,596.58. This represents a 22.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.80% of the stock is owned by corporate insiders.

Beam Therapeutics Stock Down 4.4% BEAM opened at $26.33 on Tuesday. Beam Therapeutics Inc. has a fifty-two week low of $15.60 and a fifty-two week high of $38.26. The business has a 50-day moving average of $31.47 and a 200-day moving average of $29.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 16.99 and a quick ratio of 16.99. The company has a market capitalization of $2.71 billion, a PE ratio of -38.72 and a beta of 2.18.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.12. The business had revenue of $31.74 million during the quarter, compared to analysts’ expectations of $10.98 million. Beam Therapeutics had a negative return on equity of 29.00% and a negative net margin of 39.66%.The firm’s quarterly revenue was up 323.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.23) EPS. Equities research analysts forecast that Beam Therapeutics Inc. will post -4.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth Several analysts have recently commented on BEAM shares. Citigroup raised their target price on Beam Therapeutics from $64.00 to $68.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Sanford C. Bernstein dropped their price target on Beam Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research note on Tuesday, July 7th. Bank of America restated a “buy” rating and set a $47.00 price objective on shares of Beam Therapeutics in a research report on Wednesday, July 8th. Finally, Tudor Pickering set a $39.00 target price on Beam Therapeutics in a report on Wednesday, May 13th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $46.85.

View Our Latest Research Report on BEAM

About Beam Therapeutics (Free Report)

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.

Featured Articles Five stocks we like better than Beam Therapeutics The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDeere & Company $DE Shares Sold by AlTi Global Inc.

NEXT HEADLINE »10,396 Shares in Akamai Technologies, Inc. $AKAM Acquired by AlTi Global Inc.